OUP user menu

Anaplastic Large Cell Lymphoma

L. Jeffrey Medeiros MD, Kojo S.J. Elenitoba-Johnson MD
DOI: http://dx.doi.org/10.1309/R2Q9CCUVTLRYCF3H 707-722 First published online: 1 May 2007


Session 8 of the 2005 Society of Hematopathology/European Association for Haematopathology Workshop was devoted to anaplastic large cell lymphoma (ALCL). Most cases submitted were anaplastic lymphoma kinase (ALK)+ ALCL highlighting unusual clinical settings, histologic variants, and variant translocation partners. Cases submitted as ALK– ALCL emphasized the immunohistochemical overlap with classical Hodgkin lymphoma (eg, CD15+/CD30+). It was also clear that consensus histologic and immunohistochemical criteria for the diagnosis of ALK– ALCL are lacking. Many expressed the opinion that ALK– ALCL is not a distinct entity at the immunophenotypic or genetic level and is better designated as peripheral T-cell lymphoma (PTCL), unspecified. Others suggested that the histologic features of ALK– ALCL are distinctive nevertheless and that this diagnosis has meaning that is lost by designating these neoplasms as PTCL, unspecified. This session also included CD30+ anaplastic lymphomas involving skin in which the differential diagnosis included cutaneous ALCL and systemic ALK– ALCL.

Key Words:
  • Anaplastic large cell lymphoma
  • Anaplastic lymphoma kinase
  • Classical Hodgkin lymphoma
  • Peripheral T-cell lymphoma